Dingzhi Huang - Concepedia

Author

Dingzhi Huang

Tianjin Medical University Cancer Institute and Hospital ORCID

Also Known As

Cuihua Yang, D. Huang, D. Lv, DINGZHI HUANG, Daniel Huang, Dao Lai Huang, DingZhi Huang, Dingzhi Huang, Ding‐Zhi Huang, Huang Dingzhi

128

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Tianjin Medical University Cancer Institute and Hospital Zhejiang Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Peking University Central South University

About

Dingzhi Huang is an author at Tianjin Medical University Cancer Institute and Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	16	950
2	Cell Biology	5	5	321
3	Health Sciences	3	3	52
4	Immunology	2	2	103
5	Gastroenterology	1	1	22

Dingzhi Huang

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis Haiyang Zhang, Ting Deng, Rui Liu, Nature Communications	2017	580
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study Siow Ming Lee, Christian Schulz, Kumar Prabhash, The Lancet First-line Atezolizumab MonotherapyMedicinePharmacologyClinical TrialsImmune Checkpoint Inhibitor	2023	142
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial Yun Fan, Jun Zhao, Qiming Wang, Journal of Thoracic Oncology Camrelizumab Plus ApatinibMedicinePharmacologyClinical TrialsTherapeutic Efficacy	2020	137
Exosomal miR-27a Derived from Gastric Cancer Cells Regulates the Transformation of Fibroblasts into Cancer-Associated Fibroblasts Jingya Wang, Xuwen Guan, Yue Zhang, Cellular Physiology and Biochemistry	2018	125
Cell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma Haiyang Zhang, Ming Bai, Ting Deng, Cancer Letters Tumor BiologyAngiogenesisMedicineCell-derived MicrovesiclesExtracellular Microvesicles	2016	109
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial Ying Cheng, Yun Fan, Yanqiu Zhao, Journal of Thoracic Oncology Phase 3Clinical TherapeuticPharmacologyClinical TrialsFirst-line Treatment	2024	104
Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial Caicun Zhou, Dingzhi Huang, Yun Fan, Journal of Thoracic Oncology	2022	97
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China Anwen Xiong, Lei Wang, Jianhua Chen, The Lancet MedicineImmunologyPathologyImmune Checkpoint InhibitorCancer Treatment	2025	90
Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma Jialu Li, Yang Liu, Cheng Wang, Scientific Reports	2015	86
Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer Haiyang Zhang, Jingjing Duan, Yanjun Qu, Protein & Cell	2016	78

Page 1